Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin Diseases (GUMIDIC)
Studio Sulla diversità Del Microbiota Intestinale Umano in Pazienti Con Patologie Infiammatorie Cutanee
This study will examine whether the gut bacteria of adults with inflammatory or immune-mediated skin diseases differ from those of healthy adults. It will include people with atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, or bullous pemphigoid, as well as healthy controls.
Participants will provide a stool sample and complete a short food diary. The study team will analyze the bacteria in the samples and compare the results between the disease groups and healthy controls. Participants with a skin disease will be asked to provide a second stool sample and complete follow-up assessments about six months later; healthy controls will provide one sample. The study will also examine whether changes in gut bacteria are related to skin disease severity, diet, and other collected health information.
연구 개요
상태
상태
정황
정황
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Gianluca Nazzaro, MD
- 전화번호: +39 0255035200
- 이메일: gianluca.nazzaro@policlinico.mi.it
연구 장소
-
-
-
Milan, 이탈리아, 20122
- 모병
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
-
연락하다:
- Gianluca Nazzaro, MD
- 전화번호: +39 0255035200
- 이메일: gianluca.nazzaro@policlinico.mi.it
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Adults aged 18 years or older with one of eight specialist-confirmed inflammatory or immune-mediated skin diseases, plus healthy adult controls without those diseases. Participants are recruited through the Dermatology service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy.
설명
Inclusion Criteria:
- Age 18 years or older.
- Able and willing to provide informed consent.
- For patient groups: specialist-confirmed diagnosis of atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, or bullous pemphigoid.
- For healthy controls: no diagnosis of the skin diseases studied.
Exclusion Criteria:
- Unable to provide informed consent or complete the study procedures.
- Systemic antibiotic treatment within 8 weeks before recruitment or during follow-up.
- Previous intestinal surgery.
- Inflammatory bowel disease, constipation, or diarrhea.
- Long-term alcohol use.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: CASE_CONTROL
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
|---|
|
Atopic Dermatitis
Adults aged 18 years or older with dermatologist-confirmed atopic dermatitis. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Psoriasis
Adults aged 18 years or older with dermatologist-confirmed psoriasis. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Hidradenitis Suppurativa
Adults aged 18 years or older with dermatologist-confirmed hidradenitis suppurativa. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Vitiligo
Adults aged 18 years or older with dermatologist-confirmed vitiligo. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Acne
Adults aged 18 years or older with dermatologist-confirmed acne. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Pemphigus
Adults aged 18 years or older with dermatologist-confirmed pemphigus. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Bullous Pemphigoid
Adults aged 18 years or older with dermatologist-confirmed bullous pemphigoid. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
|
Healthy Controls
Adults aged 18 years or older who do not have the skin diseases studied. Participants provide one stool sample and complete study assessments at baseline. |
|
Alopecia Areata
dults aged 18 years or older with dermatologist-confirmed alopecia areata. Participants provide a stool sample and complete study assessments at baseline and about six months later. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Relative abundance of Bifidobacteriaceae in stool
기간: Baseline (T1)
|
Compare the relative abundance of the bacterial family Bifidobacteriaceae in stool between the combined group of adults with the eight skin diseases studied and healthy controls. Relative abundance is the number of sequences assigned to Bifidobacteriaceae divided by the total number of bacterial sequences. |
Baseline (T1)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Relative abundance of Enterobacteriaceae in stool in the combined patient group
기간: Baseline (T1)
|
Compare the relative abundance of Enterobacteriaceae in stool between the combined group of adults with the eight skin diseases studied and healthy controls. |
Baseline (T1)
|
|
Relative abundance of Bifidobacteriaceae by skin-disease group
기간: Baseline (T1)
|
Compare stool Bifidobacteriaceae relative abundance between each disease group-atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, acne, pemphigus, and bullous pemphigoid-and healthy controls. |
Baseline (T1)
|
|
Relative abundance of Enterobacteriaceae by skin-disease group
기간: Baseline (T1)
|
Compare stool Enterobacteriaceae relative abundance between each of the eight disease groups and healthy controls. |
Baseline (T1)
|
|
Change in stool Bifidobacteriaceae and Enterobacteriaceae over time
기간: Baseline (T1) to 6 months (T2)
|
Assess within-person changes in the relative abundance of Bifidobacteriaceae and Enterobacteriaceae between T1 and T2 in participants with skin disease. |
Baseline (T1) to 6 months (T2)
|
|
Associations between gut bacteria and disease-related measures
기간: Baseline (T1) and 6 months (T2)
|
Explore associations between Bifidobacteriaceae and Enterobacteriaceae relative abundance and disease activity scores, psychological impact scores, available routine laboratory markers, dietary intake, and anthropometric measures, as specified in the protocol. |
Baseline (T1) and 6 months (T2)
|
공동 작업자 및 조사자
스폰서
스폰서
협력자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- GUMIDIC
- 6708 (기타 식별자: Comitato Etico Territoriale Lombardia 3)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .